Search
Regencell Bioscience Holdings Ltd
RGCAdd to Watchlist
8.030USD
+1.940+31.86%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
3.97BMarket Cap
LossP/E TTM
More Details of Regencell Bioscience Holdings Ltd Company
Regencell Bioscience Holdings Ltd is a bioscience company that focuses on research, development and commercialization of traditional Chinese medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically attention deficit and hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). The Company launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Regencell Bioscience Holdings Ltd Info
Ticker SymbolRGC
Company nameRegencell Bioscience Holdings Ltd
IPO dateJul 16, 2021
CEO- -
Number of employees12
Security typeOrdinary Share
Fiscal year-endJul 16
Address11/F, First Commercial Building, 33-35 Leighton Road, Causeway Bay
City
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryHong Kong
Postal code- -
Phone85221550823
Websitehttps://www.regencellbioscience.com/
Ticker SymbolRGC
IPO dateJul 16, 2021
CEO- -
Company Executives of Regencell Bioscience Holdings Ltd
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
Name
Name/Position
Position
Shareholding
Change
,
,
--
--
FAQs
Who are the top five shareholders of Regencell Bioscience Holdings Ltd?
The top five shareholders of Regencell Bioscience Holdings Ltd are: ,
How many institutions hold shares of Regencell Bioscience Holdings Ltd (RGC)?
As of 2026Q1, 47 institutions hold shares of Regencell Bioscience Holdings Ltd, with a combined market value of approximately 627.15K, accounting for 0.13% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -156712.00.